Law360, New York (November 19, 2008, 12:00 AM ET) -- The stakes of a patent infringement suit between AstraZeneca PLC and Teva Pharmaceuticals Ltd. over the generic version of AstraZeneca's asthma medication Pulmicort Respules have reached a new level after Teva announced Wednesday that its drug had been approved by the U.S. Food and Drug Administration despite a trial scheduled for January.
AstraZeneca wasted no time responding to the news, filing a temporary restraining order the same day in the U.S. District Court for the District of New Jersey to stop Teva from launching the generic...
AstraZeneca, Teva Patent Spat Flares Up
To view the full article, take a free trial now.
